ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M
– Series B extension co-led by AyurMaya, an affiliate of Matrix Capital Management, and Leaps by Bayer, with participation from Amgen Ventures. Adds to Existing